Etarfolatide: Clinical Trials

3 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Completed 2, Withdrawn 1
Phase 1	1	Completed 1

Follow Etarfolatide: new trials by email Literature Review of Etarfolatide trials Research Report on Etarfolatide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery EC1456, 99mTc-Etarfolatide - Ovary Cancer	Phase 1	Completed	Endocyte	3	2017-01-24	2019-02-07
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004) Vintafolide 2.5 mg, Paclitaxel 80 mg/m^2, Etarfolatide - Breast Neoplasms	Phase 2	Withdrawn	Endocyte		2014-04-01	2014-12-19
Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer EC145, EC145 + Docetaxel, Docetaxel - Non Small Cell Lung Cancer	Phase 2	Completed	Endocyte	203	2011-03-01	2021-04-01
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) Vintafolide, Etarfolatide - Adenocarcinoma of the Lung	Phase 2	Completed	Endocyte	43	2007-08-01	2015-02-27

Conditions studied

Adenocarcinoma (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Adenocarcinoma of Lung (1)  ·  Breast Neoplasms (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)

Sponsors

Endocyte (4)

Countries

Canada (1)  ·  United States (1)

Top investigators

Binh Nguyen, MD, PhD (2)  ·  Alison Armour, MB ChB, BSc, MSc, MD, MRCP (1)